Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement

Dec

11

Today In Oncology

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma

Advertisement

© 2025 HSP News Service, L.L.C.